NICE in final guidance recommends Cimzia (certolizumab pegol) from UCB and Cosentyx (secukinumab) from Novartis to treat psoriatic arthritis.
The National Institute for Health and Care Excellence (NICE) has in final guidance recommended, for the treatment of active psoriatic arthritis, the use of Cimzia (certolizumab pegol) from UCB if the patient has had a TNF alpha inhibitor but is not responding after 12 weeks. NICE has also in such guidance recommended Cosentyx (secukinumab) from Novartis in the same circumstances and where the TNF alpha inhibitor is contraindicated for the treatment of active psoriatic arthritis as monotherapy or in combination with methotrexate.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.